CTLA4 and neoplasm: One study [121] isolated exosomes from bone marrow MSCs, loaded them with siRNA targeting KRASG12D, and analyzed their effects on tumor cell KRAS signaling, FAS epigenetic regulation, and the immune microenvironment, validating their synergistic effect with anti-CTLA-4 therapy.